| Role of oxidative stress in depression S Bhatt, AN Nagappa, CR Patil Drug discovery today 25 (7), 1270-1276, 2020 | 363 | 2020 |
| Role of reactive oxygen species in the progression of Alzheimer’s disease S Bhatt, L Puli, CR Patil Drug Discovery Today 26 (3), 794-803, 2021 | 96 | 2021 |
| Etazolate rescues behavioral deficits in chronic unpredictable mild stress model: modulation of hypothalamic–pituitary–adrenal axis activity and brain-derived neurotrophic … A Jindal, R Mahesh, S Bhatt Neurochemistry international 63 (5), 465-475, 2013 | 49 | 2013 |
| Discovery of new anti-depressants from structurally novel 5-HT3 receptor antagonists: design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides R Mahesh, T Devadoss, DK Pandey, S Bhatt Bioorganic & medicinal chemistry letters 21 (4), 1253-1256, 2011 | 43 | 2011 |
| 5-HT3 receptor antagonism: a potential therapeutic approach for the treatment of depression and other disorders S Bhatt, T Devadoss, SN Manjula, J Rajangam Current neuropharmacology 19 (9), 1545, 2021 | 41 | 2021 |
| Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic–pituitary–adrenal axis … A Jindal, R Mahesh, S Bhatt Pharmacology Biochemistry and Behavior 132, 20-32, 2015 | 36 | 2015 |
| Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological … A Jindal, R Mahesh, S Bhatt Psychopharmacology 232, 623-637, 2015 | 34 | 2015 |
| Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative–an investigation using behavioral tests battery of depression R Mahesh, A Jindal, B Gautam, S Bhatt, D Pandey Biochemical and biophysical research communications 409 (4), 723-726, 2011 | 34 | 2011 |
| Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor—an approach using rodent behavioral antidepressant tests battery A Jindal, R Mahesh, B Gautam, S Bhatt, D Pandey European journal of pharmacology 689 (1-3), 125-131, 2012 | 30 | 2012 |
| Gut Microbiota Disruption in COVID-19 or Post-COVID Illness Association with severity biomarkers: A Possible Role of Pre/Pro-biotics in manipulating microflora KS Alharbi, Y Singh, S Rawat, O Afzal, ASA Altamimi, I Kazmi, ... Chemico-biological interactions 358, 109898, 2022 | 29 | 2022 |
| Design, synthesis and structure–activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression R Mahesh, T Devadoss, DK Pandey, S Bhatt, SK Yadav Bioorganic & medicinal chemistry letters 20 (22), 6773-6776, 2010 | 29 | 2010 |
| Exploring ACSL4/LPCAT3/ALOX15 and SLC7A11/GPX4/NFE2L2 as potential targets in ferroptosis-based cancer therapy G Gupta, AA Bhat, A Goyal, N Singla, S Gupta, S Sharma, S Bhatt, K Dua Future medicinal chemistry 15 (14), 1209-1212, 2023 | 26 | 2023 |
| Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases S Ashique, G De Rubis, E Sirohi, N Mishra, M Rihan, A Garg, RJ Reyes, ... Chemico-biological interactions 368, 110231, 2022 | 25 | 2022 |
| Role of brain-gut-microbiota axis in depression: emerging therapeutic avenues S Bhatt, J Kanoujia, S Mohana Lakshmi, CR Patil, G Gupta, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2023 | 24 | 2023 |
| Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (6g) on chronic unpredictable mild stress-induced changes in behavioural and brain oxidative stress … S Bhatt, M Radhakrishnan, A Jindal, T Devadoss, AK Dhar Indian journal of pharmacology 46 (2), 191, 2014 | 24 | 2014 |
| Targeting inflammation: a potential approach for the treatment of depression S Bhatt, T Devadoss, NK Jha, M Baidya, G Gupta, DK Chellappan, ... Metabolic brain disease 38 (1), 45-59, 2023 | 22 | 2023 |
| Green biogenic silver nanoparticles, therapeutic uses, recent advances, risk assessment, challenges, and future perspectives S Ashique, A Upadhyay, A Hussain, S Bag, D Chaterjee, M Rihan, ... Journal of Drug Delivery Science and Technology 77, 103876, 2022 | 19 | 2022 |
| Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases N Mishra, S Ashique, A Garg, VK Rai, K Dua, A Goyal, S Bhatt Drug Discovery Today 27 (5), 1431-1440, 2022 | 19 | 2022 |
| Molecular modifications by regulating cAMP signaling and oxidant-antioxidant defence mechanisms, produce antidepressant-like effect: A possible mechanism of etazolate … A Jindal, R Mahesh, S Bhatt, D Pandey Neurochemistry International 111, 3-11, 2017 | 18 | 2017 |
| Antidepressant potential of 5-HT3 receptor antagonist, Nn-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) R Mahesh, S Bhatt, T Devadoss, AK Jindal, BK Gautam, DK Pandey Journal of Young Pharmacists 4 (4), 235-244, 2012 | 18 | 2012 |
Mahesh RADHAKRISHNANPROFESSOR OF PHARMACY, BIRLA ISNTITUTE OF TECHNOLOGY & SCIENCE,PILANIVerified email at pilani.bits-pilani.ac.in
